| 000 | 01489 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250514225711.0 | ||
| 264 | 0 | _c20050922 | |
| 008 | 200509s 0 0 eng d | ||
| 022 | _a1538-7933 | ||
| 024 | 7 |
_a10.1111/j.1538-7836.2005.01352.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCurtis, L D | |
| 245 | 0 | 0 |
_aPharmacokinetics and pharmacodynamics of BB-10153, a thrombin-activatable plasminogen, in healthy volunteers. _h[electronic resource] |
| 260 |
_bJournal of thrombosis and haemostasis : JTH _cJun 2005 |
||
| 300 |
_a1180-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFibrin Fibrinogen Degradation Products |
| 650 | 0 | 4 |
_aFibrinogen _xdrug effects |
| 650 | 0 | 4 | _aFibrinolysis |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPharmacokinetics |
| 650 | 0 | 4 |
_aPlasminogen _xadministration & dosage |
| 650 | 0 | 4 |
_aThrombin _xmetabolism |
| 650 | 0 | 4 |
_aalpha-2-Antiplasmin _xdrug effects |
| 700 | 1 | _aBrown, A | |
| 700 | 1 | _aComer, M B | |
| 700 | 1 | _aSenior, J M | |
| 700 | 1 | _aWarrington, S | |
| 700 | 1 | _aDawson, K M | |
| 773 | 0 |
_tJournal of thrombosis and haemostasis : JTH _gvol. 3 _gno. 6 _gp. 1180-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1538-7836.2005.01352.x _zAvailable from publisher's website |
| 999 |
_c15555431 _d15555431 |
||